Salk Institute awarded $25 million grant from Helmsley Charitable Trust

November 21, 2016

LA JOLLA -- (Nov. 21, 2016) The Salk Institute for Biological Studies has received a $25 million grant -- a renewal of the largest research gift in the Institute's 56-year history -- that will be used to continue exploring an ambitious range of projects aimed at understanding the role chronic inflammation plays in driving human disease.

The grant from The Leona M. and Harry B. Helmsley Charitable Trust extends the historic $42 million Helmsley gift made to the Salk Institute in 2013. That gift established the Helmsley Center for Genomic Medicine, which enables Salk's leading scientists to delve into the genetic underpinnings of some of humankind's most devastating afflictions, and paves the way to new therapies for chronic illnesses, including cancer, diabetes, inflammatory bowel disease and Alzheimer's disease.

"Helmsley is delighted to be able to provide the Salk Institute this critical renewal grant so that its scientists are able to continue the amazing research that stems from our initial grant in 2013," says Stephanie Cuskley, chief executive officer of the Helmsley Charitable Trust. "We are honored to partner with the Salk Institute and help support its world-class researchers."

The new grant will start January 1, 2017 and provide three years of funding support for Salk research teams drawing from several areas of expertise including cancer, stem cells and metabolism. Led by senior investigators Inder Verma, Ronald Evans and Rusty Gage, scientists who will continue to be funded by Helmsley include Reuben Shaw, Juan Carlos Izpisua Belmonte, Marc Montminy, Clodagh O'Shea, Alan Saghatelian, Tony Hunter, Greg Lemke, Paul Sawchenko, Satchidananda Panda and Geoffrey Wahl. Additional support will also be provided to Jan Karlseder, Martin Hetzer, Ye Zheng, Diana Hargreaves, Janelle Ayres, Dmitry Lyumkis, Patrick Hsu and Jesse Dixon. The funding provided by the grant will continue as well to support many core facilities at the Salk Institute.

A central theme of this program is that chronic inflammation lies at the root of most of the health problems in the world today. This Helmsley grant is designed to promote collaborative interdisciplinary research that will yield new diagnostic tools, therapeutics and preventive measures for a broad range of disorders. Amazing discoveries in diabetes, neuroscience and cancer have already been made since the original grant three years ago, resulting in two clinical trials. The impact of this support is remarkable and the Salk Institute is very grateful to the Helmsley Charitable Trust for sponsoring this highly productive partnership.

With support from the existing Helmsley grant, the Salk Institute launched its successful Salk Fellows program in 2014. To date, the program has brought three scientists from broad disciplines to the Institute to trigger innovation and collaboration in single-particle cryo-electron microscopy, three-dimensional genomic organization and the gene editing technology known as CRISPR. The current Helmsley-Salk Fellows have each garnered a prestigious Director's Early Independence Award from the National Institutes of Health.

In 2009, Helmsley awarded a $5.5 million grant to establish the Salk Center for Nutritional Genomics to study nutrition at the molecular level and its impact on the role of metabolism in diabetes, obesity, cancer, exercise physiology and lifespan. Helmsley expanded support with an additional $15 million grant in 2010 to create a collaborative stem cell project involving Salk and Columbia University to fast-track the use of induced pluripotent stem cells to gain new insight into disease mechanisms and screen for novel therapeutic drugs.

Salk President Elizabeth Blackburn says the funding is vital for the pursuit of transformative research that will have worldwide impact on people's health for generations to come. "The Helmsley Charitable Trust has made extraordinary gifts to support Salk science over the past decade," says Blackburn. "We are tremendously grateful to Helmsley for their commitment to improve health and for supporting pioneering research here at the Institute."
About the Salk Institute for Biological Studies:

Every cure has a starting point. The Salk Institute embodies Jonas Salk's mission to dare to make dreams into reality. Its internationally renowned and award-winning scientists explore the very foundations of life, seeking new understandings in neuroscience, genetics, immunology and more. The Institute is an independent nonprofit organization and architectural landmark: small by choice, intimate by nature and fearless in the face of any challenge. Be it cancer or Alzheimer's, aging or diabetes, Salk is where cures begin. Learn more at

About the Helmsley Charitable Trust:

The Leona M. and Harry B. Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health, place-based initiatives, and education and human services. Since beginning its grantmaking in 2008, Helmsley has committed more than $1.5 billion for a wide range of charitable purposes. For more information, visit

Salk Institute

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to